All three FDA-approved inhibitors of CDK4/6 are now in clinical trials in combination with ICIs to treat cancers, such as breast cancer, HNSCC, NSCLC, and liver cancer (Table 2). This evidence concerns the gene CDK4 and breast carcinoma.